Journal of Cardiovascular Disease Research

ISSN: 0975-3583, 0976-2833 VOL12, ISSUE 06, 2021

COMPARATIVE EVALUATION OF RIFAXIMIN LACTULOSE COMBINATION THERAPY WITH AND WITHOUT PROBIOTICS IN HEPATIC ENCEPHALOPATHY: A COMPREHENSIVE REVIEW

NIRANJAN BABU MUDDULURU*, MUNISH KUMAR M
Department of Pharmacognosy, Seven Hills College of Pharmacy, Tirupati, A.P., India

Corresponding Author
Dr. M. Niranjan Babu
Professor
Department of Pharmacognosy
Seven Hills College of Pharmacy,
Tirupati, A.P., India – 517561
Contact: 7702484513
Email: principal.cq@jntua.ac.in

ABSTRACT:
Hepatic Encephalopathy (HE) is a neurological condition resulting from liver dysfunction. It commonly occurs in individuals with advanced liver diseases like cirrhosis. Normally, the liver filters toxins from the blood, but when it fails to do so, toxins accumulate and impair brain function. Symptoms can range from mild confusion and forgetfulness to severe disorientation and coma. Early detection and management are essential to prevent complications and improve patient outcomes. Traditional treatments for hepatic encephalopathy have focused on reducing the buildup of toxic substances in the blood, particularly ammonia, which is thought to be a key factor in symptom development. Lactulose, a synthetic sugar with laxative properties, promotes the growth of beneficial bacteria in the colon, which helps convert ammonia into a less toxic form that can be excreted in stool. Antibiotics such as neomycin or rifaximin are used to decrease the population of ammonia-producing bacteria in the gut, aiming to lower ammonia levels in the bloodstream.
Probiotics, which are live microorganisms like bacteria and yeast, offer health benefits when consumed in sufficient amounts. These "good" or "friendly" bacteria help maintain the balance of microbial communities in the digestive system and support overall health.

KEYWORDS: Hepatic Encephalopathy, Rifaximin, Lactulose, Probiotics.

INTRODUCTION

HEPATIC ENCEPHALOPATHY:

Hepatic encephalopathy (HE) is a serious and complex neurological condition that results from liver dysfunction, particularly in advanced liver disease. The liver, crucial for metabolism and detoxification, typically processes and removes toxins from the blood. However, when the liver is impaired due to conditions such as cirrhosis, hepatitis, or liver failure, harmful substances, especially ammonia, accumulate in the bloodstream and eventually impact the brain.
HE presents a range of neuropsychiatric abnormalities, from subtle cognitive impairments to severe neurological dysfunction. Symptoms include mood alterations, personality changes, confusion, and in severe cases, coma. HE is categorized into two types: overt HE, with

ISSN: 0975-3583, 0976-2833 VOL12, ISSUE 06, 2021

noticeable and significant neurological symptoms, and covert HE, involving more subtle cognitive changes that may not be immediately apparent.

The mechanisms underlying HE are multifactorial, involving the toxic effects of elevated ammonia levels, inflammation, and disruption of neurotransmitter balance in the brain. Ammonia, a byproduct of protein metabolism normally detoxified by the liver, becomes neurotoxic when its clearance is compromised. This toxic buildup disrupts neurotransmission, leading to the neurological symptoms observed in HE.

Various Precipitating Factors:

HE can be exacerbated by factors such as gastrointestinal bleeding, infections, electrolyte imbalances, and certain medications. Diagnosis involves assessing neurological symptoms, conducting laboratory tests to evaluate liver function, and sometimes using advanced imaging studies. Management focuses on addressing the underlying liver disease, reducing ammonia levels, and managing contributing factors. Treatment may include dietary restrictions, medications, and, in severe cases, liver transplantation.

HE poses a significant challenge in managing patients with advanced liver disease, impacting their quality of life and prognosis. Understanding the pathophysiology and triggers of HE is crucial for developing effective therapeutic approaches and improving outcomes for individuals affected by this debilitating condition.

Prevalence of Hepatic Encephalopathy:

The worldwide prevalence of hepatic encephalopathy varies from 30% to 62%. In India, studies have reported a prevalence of 53% to 62%. These rates can be influenced by factors like liver disease etiology, age, alcohol consumption, and surgical portosystemic shunts.

Etiology:

The most common cause of HE is cirrhosis, which results from chronic liver diseases such as chronic hepatitis, alcoholic liver disease, or non-alcoholic fatty liver disease. The extensive scarring in cirrhosis disrupts normal liver function, leading to toxin accumulation in the blood.

Portosystemic Shunting:

In cirrhotic livers, altered blood flow leads to the development of portosystemic shunts—abnormal connections between the portal vein and the systemic circulation. This bypasses the liver's detoxifying function, allowing toxins like ammonia to reach the brain.

Impaired Detoxification of Ammonia:

Ammonia, a byproduct of protein metabolism in the gastrointestinal tract, is normally converted by the liver into urea, which is then excreted via urine. In liver dysfunction, especially cirrhosis, the liver cannot efficiently detoxify ammonia, resulting in its accumulation in the bloodstream and subsequent entry into the brain.

Gastrointestinal Bleeding:

Gastrointestinal bleeding, often associated with conditions like esophageal varices in cirrhotic patients, can lead to a sudden release of large amounts of blood into the digestive tract. The breakdown of blood proteins in the gut releases additional ammonia, further contributing to HE.

Infection:

Infections, especially bacterial infections in the gut, can exacerbate HE. Gut bacteria produce ammonia, and infections can increase its production and absorption, overwhelming the impaired detoxification capacity of the damaged liver.

Electrolyte Imbalances:

Electrolyte imbalances, particularly potassium, can contribute to the development of HE. These imbalances may be exacerbated by conditions such as diuretic use or renal dysfunction, common in advanced liver disease.

Medications:

ISSN: 0975-3583, 0976-2833 VOL12, ISSUE 06, 2021

Certain medications, especially those metabolized by the liver, can contribute to HE. Sedatives, opioids, and benzodiazepines may have enhanced effects in individuals with compromised liver function.

EARLIER APPROACHES IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY

Hepatic encephalopathy is a condition characterized by cognitive and neurological dysfunction due to liver dysfunction. Traditional treatments have primarily aimed at reducing the accumulation of toxic substances in the bloodstream, particularly ammonia, which is central to symptom development.

Here are some traditional approaches used in the treatment of hepatic encephalopathy:

1. **Dietary Protein Restriction:** Limiting dietary protein intake can reduce ammonia production in the gastrointestinal tract. Since ammonia is a byproduct of protein metabolism, reducing protein intake may alleviate symptoms in some cases.
2. **Lactulose:** Lactulose, a synthetic sugar with laxative properties, promotes the growth of beneficial bacteria in the colon. This helps convert ammonia into a less toxic form that can be excreted through stool.
3. **Antibiotics:** Antibiotics such as neomycin or rifaximin are used to reduce the population of ammonia-producing bacteria in the gut. By decreasing the bacterial load, these antibiotics aim to lower ammonia levels in the bloodstream.
4. **L-Ornithine L-Aspartate (LOLA):** LOLA is an amino acid combination believed to enhance ammonia detoxification in the liver. It improves the urea cycle, facilitating the conversion of ammonia into urea for excretion.
5. **Branched-Chain Amino Acids (BCAAs):** BCAAs, including leucine, isoleucine, and valine, are essential amino acids used in managing hepatic encephalopathy. They may help improve protein synthesis and promote the formation of neurotransmitters in the brain.
6. **Zinc Supplementation:** Zinc deficiency is common in liver disease, and zinc supplementation has been suggested to positively impact hepatic encephalopathy. Zinc plays a role in the metabolism of ammonia and neurotransmitters.

ROLE OF RIFAXIMIN AND LACTULOSE COMBINATION IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY:

The combination of rifaximin and lactulose is commonly used to treat hepatic encephalopathy (HE), a neurological complication in individuals with advanced liver disease, particularly cirrhosis. Each drug targets different aspects of the condition, and their combined use aims to manage and prevent HE episodes.

RIFAXIMIN:

- **Mechanism of Action:** Rifaximin is a non-absorbable antibiotic that acts in the gut. It reduces ammonia production by decreasing the population of ammonia-producing bacteria in the intestines. Ammonia is a key factor in the development of hepatic encephalopathy.
- **Role in Treatment:** By lowering intestinal ammonia levels, rifaximin helps decrease the neurotoxic effects associated with hepatic encephalopathy. It is often used as maintenance therapy to prevent the recurrence of episodes.

LACTULOSE:

- **Mechanism of Action:** Lactulose is a synthetic sugar that is not absorbed by the body. It promotes the growth of beneficial bacteria in the colon, which convert lactulose into acids. These acids acidify the colonic contents, trapping ammonia in the colon and preventing its absorption into the bloodstream.
- **Role in Treatment:** Lactulose is commonly used to treat and prevent hepatic encephalopathy episodes. It helps reduce ammonia levels and improve the symptoms

ISSN: 0975-3583, 0976-2833 VOL12, ISSUE 06, 2021

associated with the condition. Lactulose is also considered a first-line therapy for acute episodes.

COMBINATION THERAPY:

- **Synergistic Effect:** The combination of rifaximin and lactulose is often considered to have a synergistic effect in managing hepatic encephalopathy. While rifaximin reduces ammonia production in the gut, lactulose traps ammonia and eliminates it through bowel movements.
- **Preventive Approach:** The combination is frequently used for long-term maintenance therapy to prevent the recurrence of hepatic encephalopathy episodes in individuals with a history of the condition.

PROBIOTICS:

Probiotics are live microorganisms, primarily bacteria and yeast, that provide health benefits to the host (typically humans) when consumed in adequate amounts. These microorganisms, often referred to as "good" or "friendly" bacteria, contribute to the balance of microbial communities in the digestive system and help maintain overall health.

EFFICIENCY OF PROBIOTICS ALONG WITH THE RIFAXIMIN-LACTULOSE COMBINATION:

Studies have demonstrated that the combination of rifaximin and lactulose is effective in managing hepatic encephalopathy by reducing ammonia levels and improving symptoms. Adding probiotics to this regimen may provide additional benefits by promoting a healthier gut microbiota. Probiotics can contribute to the stability and diversity of gut flora, and their inclusion may enhance patient tolerance by potentially reducing side effects associated with antibiotic use. Generally considered safe, probiotics may improve overall gastrointestinal well-being. However, treatment response can vary among individuals based on factors such as the severity of hepatic encephalopathy, patient comorbidities, and other medications being taken.

SIGNIFICANCE:

While rifaximin and lactulose are the first-line therapy for treating hepatic encephalopathy, probiotics also show effectiveness. This review highlights the benefits and effectiveness of including probiotics in the rifaximin-lactulose combination for treating hepatic encephalopathy.

DISCUSSION:

Hepatic encephalopathy is a serious neuropsychological condition that occurs during advanced liver diseases. Traditional treatments for hepatic encephalopathy include rifaximin, lactulose, LOLA, BCAAs, and zinc supplementation, often supported by dietary protein restriction. The main goal is to lower ammonia levels and improve the patient's quality of life. Emerging studies are exploring alternative therapies, with probiotics showing promising effects in treating the condition. In an era of increasing antibiotic resistance, probiotics can eliminate harmful bacteria in the intestine, reducing ammonia production without causing resistance issues. Including probiotics and other alternatives expands the possibilities for discovering new mechanisms underlying the pathophysiology of hepatic encephalopathy.

CONCLUSION

Hepatic encephalopathy (HE) is a complex and serious neurological condition that results from liver dysfunction, especially in advanced liver disease. HE can present with various symptoms, including confusion, forgetfulness, personality changes, slurred speech, and impaired coordination, and in severe cases, it can lead to coma or death. Traditional treatments have included dietary modifications, antibiotics, lactulose, and zinc supplements, all aimed at reducing the accumulation of toxic substances in the bloodstream, particularly ammonia, which is central to symptom development. Probiotics, as live microorganisms, have shown the ability to balance microbial communities in the digestive system, thereby

ISSN: 0975-3583, 0976-2833 VOL12, ISSUE 06, 2021

reducing ammonia production by bacterial colonies. The overall goal of HE treatment is to decrease ammonia production. Probiotics, along with rifaximin and lactulose, contribute to this goal and have demonstrated effectiveness in numerous studies. They are safe, economical, and clinically proven options for managing hepatic encephalopathy.

REFERENCES

1. Kumar G, Taneja A, Kandiah PA. Brain and the Liver: Cerebral Edema, Hepatic Encephalopathy and Beyond. Hepatic Critical Care. 2017:83–103.
2. Aldridge DR, Tranah EJ, Shawcross DL. Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. Journal of Clinical and Experimental Hepatology. 2015;(5):S7-20.
3. Ferenci P. Hepatic encephalopathy. Gastroenterology Report (oxford academy). 2017;5(2):138-47.
4. Jayakumar AR, Norenberg MD. Hyperammonemia in Hepatic Encephalopathy. Journal of Clinical and Experimental Hepatology. 2018;8(3):272-80.
5. Aldridge DR, Tranah EJ, Shawcross DL. Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. Journal of Clinical and Experimental Hepatology. 2015;(5):S7-20.
6. Teleanu RI, Niculescu AG, Roza E, Vladâcenco O, Grumezescu AM, Teleanu DM. Neurotransmitters-Key Factors in Neurological and Neurodegenerative Disorders of the Central Nervous System. International Journal of Molecular Sciences. 2021;23(11):5954.
7. Aamann L, Tandon P, Bémeur C. Role of Exercise in the Management of Hepatic Encephalopathy: Experience from Animal and Human Studies. Journal of Clinical and Experimental Hepatology. 2019;9(1):131-36.
8. Hammad A, Kaido T, Aliyev V, Mndato C, Uemoto S. Nutritional Therapy in Liver Transplantation. Nutrients. 2017;9(10):1126.
9. Kaplan A, Rosenblatt R. Symptom Management in Patients with Cirrhosis: A Practical Guide. Current Treatment Options in Gastroenterology. 2021;20(2):144-59.